LMLaura M. Mateyka

Laura M. Mateyka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura M. Mateyka has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Dirk H. Busch

    Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, Technical University of Munich, Munich, Germany

    2 shared publications
  • Elvira D'IPpolito

    Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany.

    2 shared publications
  • Andreas Pichlmair

    Institute of Virology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

    1 shared publication
  • Dirk H. Busch

    Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich (TUM), 81675 Munich, Germany; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

    1 shared publication
  • Henriette Riehl

    Helios Klinikum Munich West, Steinerweg 5, 81241 Munich, Germany

    1 shared publication
  • Holger Poppert

    Department of Neurology, Klinikum rechts der Isar, Technische Universität, Munich, Germany

    1 shared publication

Latest Publications

  • Open Access

    Two-Year Follow-Up on Chemosensory Dysfunction and Adaptive Immune Response after Infection with SARS-CoV-2 in a Cohort of 44 Healthcare Workers

    by Sophia E. Schambeck, Laura M. Mateyka, Teresa Burrell, Natalia Graf, Ioana Brill, Thomas Stark, Ulrike Protzer, Dirk H. Busch, Markus Gerhard, Henriette Riehl, et al.

    Persistent chemosensory dysfunction (PCD) is a common symptom of long-COVID. Chemosensory dysfunction (CD) as well as SARS-CoV-2-specific antibody levels and CD8+ T-cell immunity were investigated in a cohort of 44 healthcare workers up to a median of 721 days after a positive PCR test. CD was assessed using questionnaires and psychophysical screening tests. After 721 days, 11 of 44 (25%) participants reported PCD, with five describing an impaired quality of life. One participant reported hyperosmia (increased sense of smell). The risk of PCD at 721 days was higher for participants reporting qualitative changes (parosmia (altered smell), dysgeusia (altered taste), or phantosmia (hallucination of smell)) during initial infection than in those with isolated quantitative losses during the first COVID-19 infection (62.5% vs. 7.1%). The main recovery rate occurred within the first 100 days and did not continue until follow-up at 2 years. No correlation was found between antibody levels and CD, but we observed a trend of a higher percentage of T-cell responders in participants with CD. In conclusion, a significant proportion of patients suffer from PCD and impaired quality of life 2 years after initial infection. Qualitative changes in smell or taste during COVID-19 pose a higher risk for PCD.


  • Open Access

    Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors

    by Laura M. Mateyka, Philipp M. Strobl, Sebastian Jarosch, Sebastian J. C. Scheu, Dirk H. Busch, Elvira D’ippolito

    The importance of T cells in controlling SARS-CoV-2 infections has been demonstrated widely, but insights into the quality of these responses are still limited due to technical challenges. Indeed, understanding the functionality of the T-cell receptor (TCR) repertoire of a polyclonal antigen-specific population still requires the tedious work of T-cell cloning or TCR re-expression and subsequent characterization. In this work, we show that it is possible to discriminate highly functional and bystander TCRs based on gene signatures of T-cell activation induced by recent peptide stimulation. SARS-CoV-2-specific TCRs previously identified by cytokine release after peptide restimulation and subsequent single-cell RNA sequencing were re-expressed via CRISPR-Cas9-mediated gene editing into a Jurkat-based reporter cell line system suitable for high-throughput screening. We could observe differences in SARS-CoV-2 epitope recognition as well as a wide range of functional avidities. By correlating these in vitro TCR engineered functional data with the transcriptomic profiles of the corresponding TCR-expressing parental T cells, we could validate that gene signatures of recent T-cell activation accurately identify and predict truly SARS-CoV-2-specific TCRs. In summary, this work paves the way for alternative approaches useful for the functional analysis of global antigen-specific TCR repertoires with largely improved throughput.


  • Open Access

    SARS-CoV-2 CD8+ T cell killing assays using replicating viruses and transgenic antigens

    by Laura M. Mateyka, Vincent Grass, Andreas Pichlmair, Dirk H. Busch, Elvira D’IPpolito